Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Tancini

Showing results (21-30 of 218) with videos related to

Pageof 22
Sort By:
Tumori|June 30, 1993
Prevention by L-carnitine of interleukin-2 related cardiac toxicity during cancer immunotherapyP Lissoni, M A Galli, G Tancini, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1984
CMF adjuvant programs at the Milan Cancer InstituteG Bonadonna, A Rossi, G Tancini, et al.
Tumori|November 1, 1995
Endocrine effects of granulocyte colony-stimulating factor in cancer patientsF Rovelli, S Barni, G Tancini, et al.
Tumori|June 30, 1988
Endocrine and clinical effects of an LHRH analogue in pretreated advanced breast cancerP Lissoni, S Barni, S Crispino, et al.
Tumori|December 31, 1993
Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance statusP Lissoni, F Brivio, A Ardizzoia, et al.
The International Journal of Biological Markers|October 1, 1988
Soluble interleukin-2 receptor levels in Hodgkin's disease: preliminary considerations about their prognostic significanceP Lissoni, S Barni, F Rovelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1983
Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cyclesG Tancini, G Bonadonna, P Valagussa, et al.
British Journal of Cancer|October 1, 1989
Serum levels of soluble interleukin-2 receptors and their relation to lymphocyte subpopulations in patients with metastatic solid tumoursP Lissoni, S Barni, R Rescaldani, et al.
European Journal of Cancer & Clinical Oncology|May 1, 1989
Endocrine and immune effects of melatonin therapy in metastatic cancer patientsP Lissoni, S Barni, S Crispino, et al.
The International Journal of Biological Markers|October 1, 1989
Serum levels of interleukin-2 in cancer patients: preliminary considerationsP Lissoni, S Viviani, A Santoro, et al.
Pageof 22

Showing results (21-30 of 218) with videos related to

Sort By:
Pageof 22
Tumori|June 30, 1993
Prevention by L-carnitine of interleukin-2 related cardiac toxicity during cancer immunotherapyP Lissoni, M A Galli, G Tancini, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1984
CMF adjuvant programs at the Milan Cancer InstituteG Bonadonna, A Rossi, G Tancini, et al.
Tumori|November 1, 1995
Endocrine effects of granulocyte colony-stimulating factor in cancer patientsF Rovelli, S Barni, G Tancini, et al.
Tumori|June 30, 1988
Endocrine and clinical effects of an LHRH analogue in pretreated advanced breast cancerP Lissoni, S Barni, S Crispino, et al.
Tumori|December 31, 1993
Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance statusP Lissoni, F Brivio, A Ardizzoia, et al.
The International Journal of Biological Markers|October 1, 1988
Soluble interleukin-2 receptor levels in Hodgkin's disease: preliminary considerations about their prognostic significanceP Lissoni, S Barni, F Rovelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1983
Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cyclesG Tancini, G Bonadonna, P Valagussa, et al.
British Journal of Cancer|October 1, 1989
Serum levels of soluble interleukin-2 receptors and their relation to lymphocyte subpopulations in patients with metastatic solid tumoursP Lissoni, S Barni, R Rescaldani, et al.
European Journal of Cancer & Clinical Oncology|May 1, 1989
Endocrine and immune effects of melatonin therapy in metastatic cancer patientsP Lissoni, S Barni, S Crispino, et al.
The International Journal of Biological Markers|October 1, 1989
Serum levels of interleukin-2 in cancer patients: preliminary considerationsP Lissoni, S Viviani, A Santoro, et al.
Pageof 22